Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia-Reference-Cited by-同舟云学术

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

Published:2020-11-24 Issue:6 Volume:127 Page:905-913
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Stock Wendy¹,Martinelli Giovanni²,Stelljes Matthias³,DeAngelo Daniel J.⁴,Gökbuget Nicola⁵,Advani Anjali S.⁶,O’Brien Susan⁷,Liedtke Michaela⁸,Merchant Akil A.⁹,Cassaday Ryan D.¹⁰^ORCID,Wang Tao¹¹,Zhang Hui¹²,Vandendries Erik¹¹,Jabbour Elias¹³^ORCID,Marks David I.¹⁴,Kantarjian Hagop M.¹³^ORCID

Affiliation:

1. Section of Hematology/Oncology Department of Medicine, and University of Chicago Comprehensive Cancer Center University of Chicago Chicago Illinois

2. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS Meldola Italy

3. Universitätsklinikum Münster Münster Germany

4. Dana‐Farber Cancer Institute Boston Massachusetts

5. Goethe University Frankfurt Germany

6. Cleveland Clinic Taussig Cancer Institute Cleveland Ohio

7. Chao Family Comprehensive Cancer Center University of California Irvine Orange California

8. Stanford Cancer Institute Stanford California

9. Cedars Sinai Medical Center Los Angeles California

10. University of Washington School of Medicine and Fred Hutchinson Cancer Research Center Seattle Washington

11. Pfizer Inc Cambridge Massachusetts

12. Pfizer Inc Shanghai China

13. University of Texas MD Anderson Cancer Center Houston Texas